Rheumatoid arthritis: New developments in the use of existing therapies

J. R. O'Dell, D. L. Scott

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Combination therapy with methotrexate may be the newest standard to which future therapies for rheumatoid arthritis are compared. Many questions remain to be answered regarding the appropriateness of such combination therapies for specific patients and clinical situations, and the optimal therapeutic combinations. Other unanswered questions regarding combination therapy include the need for appropriate monitoring, long-term safety and cost-benefit implications. Future research is needed to clarify the role of biological response modifiers (e.g. anti-tumour necrosis factor therapies) and matrix metalloproteinase inhibitors, both as components of and alternatives to methotrexate combination regimens.

Original languageEnglish (US)
Pages (from-to)24-26
Number of pages3
JournalRheumatology
Volume38
Issue numberSUPPL. 2
StatePublished - Nov 1999

    Fingerprint

Keywords

  • Biological response modifiers
  • Combination therapy
  • Cyclosporin
  • Hydroxychloroquine
  • Leflunomide
  • Metalloproteinase inhibitors
  • Methotrexate
  • Sulphasalazine

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this